Results 81 to 90 of about 5,337 (191)

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease

Molecules
The most prevalent chronic neurodegenerative illness in the world is Alzheimer’s disease (AD). It results in mental symptoms including behavioral abnormalities and cognitive impairment, which have a substantial financial and psychological impact on the ...
Amin Mahmood Thawabteh, Aseel Wasel Ghanem, Sara AbuMadi, Dania Thaher, Weam Jaghama, Donia Karaman, Rafik Karaman   +6 more
doaj   +1 more source

Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review

Alzheimer’s Research & Therapy, 2023
Key points of disagreement between the aducanumab FDA statistical review, which had primarily negative conclusions, and the clinical review, which had primarily positive conclusions, were investigated.
Samuel P. Dickson, Sean Hennessey, Jessie Nicodemus Johnson, Newman Knowlton, Suzanne B. Hendrix   +4 more
doaj   +1 more source

Volume change with gantenerumab: Impact of amyloid‐related imaging abnormalities and amyloid removal

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION Amyloid‐lowering antibodies are associated with neuroanatomical volume changes. This study aims to disentangle the contributions of amyloid‐related imaging abnormalities (ARIA) and amyloid clearance to these changes. METHODS Data from the GRADUATE I and II trials of gantenerumab in early Alzheimer's disease were analyzed ...
Matteo Tonietto, Erica Silvestri, Christopher R. S. Belder, Frederik Barkhof, Nick C. Fox, Janice Smith, Gregory Klein   +6 more
wiley   +1 more source

Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy

Frontiers in Radiology
Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been aimed at symptom relief rather than disease modification.
Houman Sotoudeh, Mohammadreza Alizadeh, Ramin Shahidi, Parnian Shobeiri, Zahra Saadatpour, C. Austin Wheeler, Marissa Natelson Love, Manoj Tanwar   +7 more
doaj   +1 more source

Beyond the Cochrane review: Re‐evaluating anti‐amyloid therapy in Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract The global burden of Alzheimer's disease (AD) is accelerating, with U.S. prevalence projected to reach nearly 13 million by 2060. Although the “amyloid cascade hypothesis” has long‐guided drug development, a 2026 Cochrane review challenged amyloid beta (Aβ) targets for therapy by citing insufficient clinical benefit and safety concerns.
Megan M. Bernath, Jared Brosch, Andrew J. Saykin, Donna Wilcock, Diana Summanwar, Deanna R. Willis   +5 more
wiley   +1 more source

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β

, 2018
Aducanumab, a human-derived antibody targeting amyloid-β (Aβ), is in Phase 3 clinical trials for the treatment of Alzheimer’s disease. Biochemical and structural analyses show that aducanumab binds a linear epitope formed by amino acids 3–7 of the Aβ ...
Thierry Bussière, Joseph W. Arndt, Benjamin A. Smith, Fang Qian, Thomas Walz, Krishna Praneeth Kilambi, Martin W. Bush, R. Blake Pepinsky, Thomas O. Cameron, Stefan Hamann, Paul H. Weinreb, Chao Quan   +11 more
core   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

, 2016
Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration.
Nitsch, Roger M, Sandrock, Alfred, Chollate, Sowmya, Maier, Marcel, Bussière, Thierry, Alfred Sandrock, Sevigny, Jeff, Dunstan, Robert, Yan Ling, James Ferrero, Williams, Leslie, Fang Qian, Weinreb, Paul H, Stephen Salloway, Sowmya Chollate, Jeff Sevigny, Hang, Yaming, Salloway, Stephen, Ling, Yan, Arnold, H Moore, Robert H. Scannevin, Scannevin, Robert H, Robert Dunstan, Mikulskis, Alvydas, Quintero-Monzon, Omar, Paul H. Weinreb, Thierry Bussière, Brennan, Melanie S, Jan Grimm, Yaming Hang, Ping Chiao, Roger M. Nitsch, Tianle Chen, Li, Mingwei, Mahin Arastu, Chen, Tianle, Grimm, Jan, Omar Quintero-Monzon, H. Moore Arnold, Chiao, Ping, Ferrero, James, Engber, Thomas, Kenneth Rhodes, Arastu, Mahin, John O’Gorman, Qian, Fang, Leslie Williams, Mingwei Li, Christoph Hock, Hock, Christoph, O'Gorman, John, Marcel Maier, Melanie S. Brennan, Alvydas Mikulskis, Rhodes, Kenneth, Thomas Engber   +55 more
core   +1 more source

Carboranyl‐Curcuminoids for the Neutron Capture‐Based Treatment of Amyloid Aggregates in Alzheimer's Disease

Advanced Science, Volume 13, Issue 39, 13 July 2026.
The 10B‐enriched monocarbonyl analog of curcumin (BMAC) 10B‐9 enables site‐specific Boron Neutron Capture Therapy (BNCT) on amyloid‐β (Aβ) fibrils. Neutron irradiation induces histidine oxidation and fibril destabilization, as revealed by 1H‐NMR and FESEM analyses.
Sebastiano Micocci, Stefano Parisotto, Diego Alberti, Alberto Lanfranco, Valeria Bitonto, Polyssena Renzi, Martina Salmi, Andrea Magnani, Federica Dal Bello, Katiuscia Pagano, Laura Ragona, Nicoletta Protti, Annamaria Deagostino, Simonetta Geninatti Crich   +13 more
wiley   +1 more source

Divergent Roles of mGlu2 and mGlu3 Receptors in Amyloid‐β Production and Cognitive Dysfunctions in Alzheimer's Disease

Advanced Science, Volume 13, Issue 37, 3 July 2026.
This study explores the opposing effects of the mGluR2 and mGluR3 receptors on amyloid precursor protein processing. mGluR2 promotes amyloidogenic cleavage, while mGluR3 favors non‐amyloidogenic pathways. Using a brain‐penetrant nanobody as a mGluR2 positive allosteric modulator, the study uncovers how its chronic activation aggravates amyloid‐β burden
Pierre‐André Lafon, Mireille Elodie Tsitokana, Ugo Guy Alenda, Yen‐Ling Lian, Clémentine Eva Philibert, Mathieu Oosterlaken, Marta Cimadevila, Gaëlle Dudon, Jessica Monnic, Salomé Roux, Julie Bessié, Séverine Diem, Franck Vandermoere, Laurent Prézeau, Patrick Chames, Julie Kniazeff, Sylvie Claeysen, Anaïs Menny, Jean‐Philippe Pin, Véronique Perrier, Jianfeng Liu, Philippe Rondard   +21 more
wiley   +1 more source